Extended Research Article
Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis
Ruben Mujica-Mota
,
Jo Varley-Campbell
,
Irina Tikhonova
,
Chris Cooper
,
Ed Griffin
,
Marcela Haasova
et al.
-
Journal:
Health Technology Assessment Volume: 22, Issue: 49
-
Published:
13 September 2018